Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026)
Fortrea Holdings (FTRE) posted Cost of Revenue of $512.9 million for Q1 2026, down 3.12% on a QoQ basis from $529.4 million in Q4 2025, and down 4.09% year-over-year from $534.8 million in Q1 2025.
Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings' Cost of Revenue history runs 5 years deep, the most recent figure standing at $512.9 million for Q1 2026.
- Quarterly Cost of Revenue fell 4.09% year-over-year to $512.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 2.56% YoY) and the FY2025 annual result came in at $2.2 billion, up 2.65% from the prior year.
- Cost of Revenue was $512.9 million for Q1 2026 at Fortrea Holdings, down from $529.4 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $614.3 million in Q2 2022 and bottomed at $265.0 million in Q4 2022.
- A 5-year average of $538.8 million and a median of $555.2 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue jumped 118.08% — and 2024, when it declined 7.63%.
- Fortrea Holdings' Cost of Revenue stood at $265.0 million in 2022, then soared by 118.08% to $577.9 million in 2023, then retreated by 3.77% to $556.1 million in 2024, then decreased by 4.8% to $529.4 million in 2025, then retreated by 3.12% to $512.9 million in 2026.
- Business Quant data shows FTRE's Cost of Revenue at $512.9 million in Q1 2026, $529.4 million in Q4 2025, and $578.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Fortrea Holdings | 1.79 Bn | 1.64 Bn | 123.60 Mn | 512.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 512.90 Mn |
| Mar 31, 2026 | 512.90 Mn |
| Dec 31, 2025 | 529.40 Mn |
| Dec 31, 2025 | 529.40 Mn |
| Sep 30, 2025 | 578.60 Mn |
| Sep 30, 2025 | 578.60 Mn |
| Jun 30, 2025 | 576.80 Mn |
| Jun 30, 2025 | 576.80 Mn |
| Mar 31, 2025 | 534.80 Mn |
| Mar 31, 2025 | 534.80 Mn |
| Dec 31, 2024 | 556.10 Mn |
| Dec 31, 2024 | 556.10 Mn |
| Sep 30, 2024 | 526.60 Mn |
| Sep 30, 2024 | 526.60 Mn |
| Jun 30, 2024 | 525.30 Mn |
| Jun 30, 2024 | 525.30 Mn |
| Mar 31, 2024 | 554.20 Mn |
| Mar 31, 2024 | 554.20 Mn |
| Dec 31, 2023 | 577.90 Mn |
| Dec 31, 2023 | 577.90 Mn |